Publications by PDCMDC Members

Collapse All | Expand All

• Adam OR, Ferrara JM, Aguilar Tabora LG, Nashatizadeh MM, Negoita M, Jankovic J. Education Research: patient telephone calls in a movement disorders center: lessons in physician-trainee education. Neurology. 2009;73:e50-2.
• Adam OR, Ferrara JM, Jankovic J. Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord. 2009;:.
• Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol. 2009;256:320-32.
• Ferrara J, Jankovic J. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009;11:293-307.
• Ferrara JM, Adam OR, Ondo WG. Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation. Mov Disord. 2009;24:149-51.
• Ferrara JM, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J. Impact of STN-DBS on Life and Health Satisfaction in Patients with Parkinson Disease. J Neurol Neurosurg Psychiatry. 2009;:.
• Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285:195-7.
• Freeman RD, Zinner SH, Muller-Vahl KR, Fast DK, Burd LJ, Kano Y, Rothenberger A, Roessner V, Kerbeshian J, Stern JS, Jankovic J, Loughin T, Janik P, Shady G, Robertson MM, Lang AE, Budman C, Magor A, Bruun R, Berlin CM, Jr. Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009;51:218-27.
• Guo Y, Jankovic J, Zhu S, Le W, Song Z, Xie W, Liao D, Yang H, Deng H. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009;454:209-11.
• Gupta A, Jankovic J. Spinocerebellar ataxia 8: Variable phenotype and unique pathogenesis. Parkinsonism Relat Disord. 2009;:.
• Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24:647-54.
• Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009;24:564-73.
• Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, Montine TJ, Pan S, Nutt J, Albin R, Gearing M, Beyer RP, Shi M, Zhang J. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2009;:.
• Jankovic J, Albanese A, Hallett M. Unique properties of botulinum toxins. Toxicon. 2009;54:675.
• Jankovic J, Albanese A. Unique Properties of Botulinum Toxins. Toxicon. 2009;:.
• Jankovic J, Jimenez-Shahed J, Brown L. A Randomized, Double-Blind, Placebo-Controlled Study of Topiramate in the Treatment of Tourette Syndrome. J Neurol Neurosurg Psychiatry. 2009;:.
• Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24:407-13.
• Jankovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284:177-8.
• Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54:614-23.
• Jankovic J. Peripherally induced movement disorders. Neurol Clin. 2009;27:821-32, vii.
• Jankovic J. This issue of Neurologic Clinics is dedicated entirely to movement disorders. Preface. Neurol Clin. 2009;27:ix-x.
• Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8:844-56.
• Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009;15:28-35.
• Le W, Nguyen D, Lin XW, Rawal P, Huang M, Ding Y, Xie W, Deng H, Jankovic J. Transcription factor PITX3 gene in Parkinson's disease. Neurobiol Aging. 2009;:.
• LeWitt PA, Ondo WG, Van Lunen B, Bottini PB. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009;32:89-93.
• Mata IF, Hutter CM, Gonzalez-Fernandez MC, de Pancorbo MM, Lezcano E, Huerta C, Blazquez M, Ribacoba R, Guisasola LM, Salvador C, Gomez-Esteban JC, Zarranz JJ, Infante J, Jankovic J, Deng H, Edwards KL, Alvarez V, Zabetian CP. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009;:.
• Ondo WG. Restless legs syndrome. Neurol Clin. 2009;27:779-99, vii.
• Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. Rapamycin Protects Against Rotenone-Induced Apoptosis Through Autophagy Induction. Neuroscience. 2009;:.
• Ravina B, Elm J, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009;24:1306-11.
• Sitburana O, Chen Wu LJ, Sheffield JK, Davidson A, Jankovic J. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009;:.
• Sitburana O, Ondo WG. Brain magnetic resonance imaging (MRI) in parkinsonian disorders. Parkinsonism Relat Disord. 2009;15:165-74.
• Strutt AM, Lai EC, Jankovic J, Atassi F, Soety EM, Levin HS, Grossman RG, York MK. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009;71:551-8.
• Tagliati M, Jankovic J, Pagan F, Susatia F, Isaias IU, Okun MS. Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage. 2009;47 Suppl 2:T53-7.
• Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Clin Neuropharmacol. 2009;:.
• Walters AS, Ondo WG, Zhu W, Le W. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study. J Neurol Sci. 2009;279:62-5.
• Wijemanne S, Jankovic J. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009;24:583-9.

Collapse All | Expand All

• Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181-97.
• Ashoori A, Jankovic J. Mozart's movements and behaviour: a case of Tourette's syndrome? Postgrad Med J. 2008;84:313-7.
• Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008;45:3878-88.
• Atassi MZ, Jankovic J, Dolimbek BZ. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008;71:1040; author reply 1040-1.
• Azher SN, Jankovic J. Clinical aspects of progressive supranuclear palsy. Handb Clin Neurol. 2008;89:461-73.
• Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353-60.
• Deng H, Le W, Shahed J, Xie W, Jankovic J. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008;430:18-22.
• Deng H, Le WD, Jankovic J. Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008;448:180-3.
• Dulay MF, Strutt AM, Levin HS, Jankovic J, Lai EC, Grossman RG, York MK. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008;20:357-63.
• Erer S, Jankovic J. Adult onset tics after peripheral injury. Parkinsonism Relat Disord. 2008;14:75-6.
• Ferrara J, Gupta D, Foster E, Garman K, Stacy M. Extraocular muscle dystonia due to acquired (non-Wilsonian) hepatocerebral degeneration. Mov Disord. 2008;23:875-8.
• Ferrara J, Jankovic J. Psychogenic movement disorders in children. Mov Disord. 2008;23:1875-81.
• Ferrara JM, Stacy M. Impulse-control disorders in Parkinson's disease. CNS Spectr. 2008;13:690-8.
• Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31:127-33.
• Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129-70.
• Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008;71:1275-82.
• Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008;4:743-57.
• Jankovic J, Ashoori A. Movement disorders in musicians. Mov Disord. 2008;23:1957-65.
• Jankovic J. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008;63:267-9.
• Jankovic J. Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008;7:9-11.
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-76.
• Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48:379-84.
• Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115:585-591.
• Kenney C, Jankovic J. Reply: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2008;23:1793.
• Kuo SH, Jankovic J. Tardive gait. Clin Neurol Neurosurg. 2008;110:198-201.
• Kuo SH, Kenney C, Jankovic J. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008;23:616-9.
• Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, Zhang X, Deng H, Jankovic J. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008;273:29-33.
• Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008;26 Suppl 1:43-53.
• Moore ST, Macdougall HG, Gracies JM, Ondo WG. Locomotor response to levodopa in fluctuating Parkinson's disease. Exp Brain Res. 2008;184:469-78.
• Moore ST, Macdougall HG, Ondo WG. Ambulatory monitoring of freezing of gait in Parkinson's disease. J Neurosci Methods. 2008;167:340-8.
• Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23:2194-201.
• Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol. 2008;23:435-7.
• Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14:28-32.
• Ondo WG, Perkins T, Swick T, Hull KL, Jr., Jimenez JE, Garris TS, Pardi D. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65:1337-40.
• Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Oh JH, Gao J, Zhang J, Montine T, Zhang J. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008;7:720-30.
• Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008;131:1969-78.
• Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008;32:16-25.
• Pan T, Zhu W, Zhao H, Deng H, Xie W, Jankovic J, Le W. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008;1222:222-9.
• Satija P, Ondo WG. Restless legs syndrome: pathophysiology, diagnosis and treatment. CNS Drugs. 2008;22:497-518.
• Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699-706.
• Sitburana O, Jankovic J. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008;266:31-3.
• Sitburana O, Ondo WG. Task-specific focal hand dystonia in a professional pistol-shooter. Clin Neurol Neurosurg. 2008;110:423-4.
• Sitburana O, Rountree S, Ondo WG. Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs. J Neurol Sci. 2008;272:77-82.
• Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008;14:253-4.
• Stamey W, Jankovic J. Impulse Control Disorders and Pathological Gambling in Patients With Parkinson Disease. Neurologist. 2008;14:89-99.
• Truong D, Comella C, Fernandez HH, Ondo WG. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14:407-14.
• Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, Ragone L, Pahwa R, Jankovic J, Nance M, Freeman A, Watts RL, Hentati F. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008;14:77-80.
• Wu LJ, Sitburana O, Davidson A, Jankovic J. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008;23:2307-11.
• York MK, Dulay M, Macias A, Levin HS, Grossman R, Simpson R, Jankovic J. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008;79:789-95.
• Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129:526-9.
• Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, Le W. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008;105:1970-8.

Collapse All | Expand All

• Adair JC, Cooke N, Jankovic J. Alexia without agraphia in Creutzfeldt-Jakob disease. J Neurol Sci. 2007;263:208-10.
• Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8.
• Ashoori A, Jankovic J. Mozart's movements and behaviour: a case of Tourette's syndrome? J Neurol Neurosurg Psychiatry. 2007;78:1171-5.
• Atassi MZ, Dolimbek BZ, Deitiker P, Jankovic J, Aoki KR. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007;20:15-21.
• Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord. 2007;22:1901-11.
• Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007;22:1743-50.
• Deng H, Le W, Huang M, Xie W, Pan T, Jankovic J. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007;419:104-7.
• Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain. 2007;130:1456-64.
• Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007;64:421-4.
• Diamond A, Kenney C, Almaguer M, Jankovic J. Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report. J Neurosurg. 2007;107:1036-8.
• Diamond A, Shahed J, Jankovic J. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007;260:199-203.
• Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44:1029-41.
• Erer S, Jankovic J. Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007;109:784-5.
• Ferrara JM, Skeen MB, Edwards NJ, Gray L, Massey EW. Subacute combined degeneration due to copper deficiency. J Neuroimaging. 2007;17:375-7.
• Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22:41-7.
• Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69:1542-50.
• Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, Leppert D, Surh L, Reeves KH, Thomas S, Ragone L, Hattori N, Pahwa R, Jankovic J, Nance M, Freeman A, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22:55-61.
• Jankovic J, Deng H. Candidate locus for chorea and tic disorders at 15q? Pediatr Neurol. 2007;37:70-3.
• Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21:677-92.
• Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13:411-6.
• Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64:676-82.
• Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007;263:94-9.
• Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22:10-3.
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22:193-7.
• Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother. 2007;8:1329-35.
• Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2007;22:127-30.
• Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, Jankovic J. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106:621-5.
• LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30:256-65.
• Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007;22:1623-9.
• May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007;22:2371-7.
• Moore ST, MacDougall HG, Gracies JM, Cohen HS, Ondo WG. Long-term monitoring of gait in Parkinson's disease. Gait Posture. 2007;26:200-7.
• Ondo WG, Meilak C, Vuong KD. Predictors of battery life for the Activa Soletra 7426 Neurostimulator. Parkinsonism Relat Disord. 2007;13:240-2.
• Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13:453-4.
• Ondo WG, Satija P. Withdrawal of visual feedback improves micrographia in Parkinson's disease. Mov Disord. 2007;22:2130-1.
• Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and 'wearing off' symptoms. Clin Neuropharmacol. 2007;30:295-300.
• Ondo WG, Zhao HR, Le WD. Animal models of restless legs syndrome. Sleep Med. 2007;8:344-8.
• Ondo WG. Placebo response in Parkinson trials using patient diaries: sites do matter. Clin Neuropharmacol. 2007;30:301-4.
• Ondo WG. Zonisamide for essential tremor. Clin Neuropharmacol. 2007;30:345-9.
• Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007;22:546-9.
• Qu S, Le W, Zhang X, Xie W, Zhang A, Ondo WG. Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol. 2007;66:383-8.
• Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69:342-7.
• Raznatovic M, Maksimovic N, Jankovic J, Music D. [Impact of some constitutional characteristics on the development of basal cell carcinoma]. Vojnosanit Pregl. 2007;64:375-9.
• Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007;13:67-76.
• Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology. 2007;68:159-60.
• Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007;7:637-47.
• Stacy MA, Elble RJ, Ondo WG, Wu SC, Hulihan J. Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor. Mov Disord. 2007;22:833-8.
• Stamey W, Jankovic J. The other Babinski sign in hemifacial spasm. Neurology. 2007;69:402-4.
• Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007;252:113-20.
• Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272-6.
• Wijemanne S, Jankovic J. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007;69:1585-94.
• Wu YC, Zhao YB, Tang MG, Zhang-Nunes SX, McArthur JC. AIDS dementia complex in China. J Clin Neurosci. 2007;14:8-11.
• Xu Y, Cai Y, Gong N, Chen C, Wu Y, Zhang-Nunes S, Wang Z, Xu T, Fei J. Homeostatic plasticity of GABAergic synaptic transmission in mice lacking GAT1. Biochem Biophys Res Commun. 2007;361:499-504.
• York MK, Lai EC, Jankovic J, Macias A, Atassi F, Levin HS, Grossman RG. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007;149:857-66; discussion 866.
• Zhao H, Zhu W, Pan T, Xie W, Zhang A, Ondo WG, Le W. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res. 2007;85:1065-76.
• Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb J. 2007;21:3835-44.

Collapse All | Expand All

• Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9:293-348.
• Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006;21:1856-63.
• Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006;21:1500-2.
• Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006;21:916-23.
• Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006;494:495-514.
• Collins A, Jankovic J. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006;67:1083-5.
• Deng H, Le W, Davidson AL, Xie W, Jankovic J. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006;407:97-100.
• Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006;251:102-6.
• Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, Jankovic J. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006;63:273-7.
• Deng H, Le WD, Xie WJ, Jankovic J. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006;114:400-2.
• Deng H, Xie W, Guo Y, Le W, Jankovic J. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006;21:728-9.
• Deng H, Xie WJ, Le WD, Huang MS, Jankovic J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006;401:16-9.
• Diamond A, Jankovic J. Botulinum toxin in dermatology - beyond wrinkles and sweat. J Cosmet Dermatol. 2006;5:169.
• Diamond A, Jankovic J. Treatment of advanced Parkinson's disease. Expert Rev Neurother. 2006;6:1181-97.
• Diamond A, Kenney C, Jankovic J. Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy. Mov Disord. 2006;21:1273-5.
• Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006;21:692-5.
• Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006;21:2078-81.
• Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006;21:306-9.
• Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67:2233-5.
• Jankovic J, Kwak C, Frankoff R. Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006;18:86-95.
• Jankovic J, Mejia NI. Tics associated with other disorders. Adv Neurol. 2006;99:61-8.
• Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome. CNS Spectr. 2006;11:501-8.
• Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006;73:682-9.
• Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9:145-8.
• Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5:864-72.
• Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, Sokoloff P. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006;103:10753-8.
• Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29:259-64.
• Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6:7-17.
• Lang AE, Houeto JL, Krack P, Kubu C, Lyons KE, Moro E, Ondo W, Pahwa R, Poewe W, Troster AI, Uitti R, Voon V. Deep brain stimulation: preoperative issues. Mov Disord. 2006;21 Suppl 14:S171-96.
• Maksimovic N, Raznatovic M, Marinkovic J, Jankovic J. [Exposure to sun radiation as a risk factor for the occurrence of basal cell carcinoma in the Montenegrian population]. Vojnosanit Pregl. 2006;63:643-7.
• Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, Erenberg G, Jankovic J, Juncos J, Leckman JF, Swerdlow N, Visser-Vandewalle V, Vitek JL. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006;21:1831-8.
• Ondo W. VIM deep brain stimulation does not improve pre-existing restless legs syndrome in patients with essential tremor. Parkinsonism Relat Disord. 2006;12:113-4.
• Ondo WG, Almaguer M, Cohen H. Computerized posturography balance assessment of patients with bilateral ventralis intermedius nuclei deep brain stimulation. Mov Disord. 2006;21:2243-7.
• Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006;66:672-7.
• Ondo WG, Lai D. Association between restless legs syndrome and essential tremor. Mov Disord. 2006;21:515-8.
• Ondo WG, Silay Y, Almaguer M, Jankovic J. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006;21:1252-4.
• Ondo WG, Silay YS. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial. Mov Disord. 2006;21:1614-7.
• Ondo WG. Essential tremor: treatment options. Curr Treat Options Neurol. 2006;8:256-67.
• Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-95.
• Pahwa R, Lyons KE, Wilkinson SB, Simpson RK, Jr., Ondo WG, Tarsy D, Norregaard T, Hubble JP, Smith DA, Hauser RA, Jankovic J. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104:506-12.
• Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138-48.
• Qu S, Ondo WG, Zhang X, Xie WJ, Pan TH, Le WD. Projections of diencephalic dopamine neurons into the spinal cord in mice. Exp Brain Res. 2006;168:152-6.
• Scahill L, Erenberg G, Berlin CM, Jr., Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3:192-206.
• Shatunov A, Sambuughin N, Jankovic J, Elble R, Lee HS, Singleton AB, Dagvadorj A, Ji J, Zhang Y, Kimonis VE, Hardy J, Hallett M, Goldfarb LG. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006;129:2318-31.
• Sitburana O, Ondo WG. Tetrabenazine for hyperglycemic-induced hemichorea-hemiballismus. Mov Disord. 2006;21:2023-5.
• Tan EK, Jankovic J. Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol. 2006;63:1232-7.
• Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006;12:382-7.
• Wu LJ, Jankovic J. Runner's dystonia. J Neurol Sci. 2006;251:73-6.
• Wu YC, Cai YQ, Zhao YB, Fei J. [Effects of Nurr1 down-regulation on the expression of tyrosine hydroxylase and neurite extension in dopaminergic cells.]. Sheng Li Xue Bao. 2006;58:351-8.

Collapse All | Expand All

• Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005;4:423-31.
• Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65:355-9.
• Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423-9.
• Deng H, Jankovic J, Guo Y, Xie W, Le W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun. 2005;337:1133-8.
• Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005;57:933-4.
• Deng H, Le WD, Guo Y, Huang MS, Xie WJ, Jankovic J. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005;65:651-2.
• Deng H, Le WD, Xie WJ, Pan TH, Zhang X, Jankovic J. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005;382:297-9.
• Deng H, Le WD, Zhang X, Pan TH, Jankovic J. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005;111:351-2.
• Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005;76:1188-93.
• Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;64:417-21.
• Imam SZ, Jankovic J, Ali SF, Skinner JT, Xie W, Conneely OM, Le WD. Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. Faseb J. 2005;19:1441-50.
• Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005;77:128-38.
• Jankovic J, Noebels JL. Genetic mouse models of essential tremor: are they essential? J Clin Invest. 2005;115:584-6.
• Jankovic J. Dystonia and other deformities in Parkinson's disease. J Neurol Sci. 2005;239:1-3.
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005;20 Suppl 11:S11-6.
• Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol. 2005;62:351-2.
• Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005;64:2021-8.
• Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005;191:154-62.
• Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005;20:86-9.
• Mejia NI, Jankovic J. Secondary tics and tourettism. Rev Bras Psiquiatr. 2005;27:11-7.
• Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20:592-7.
• Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005;20 Suppl 11:S3-10.
• Ondo WG, Bronte-Stewart H. The North American survey of placement and adjustment strategies for deep brain stimulation. Stereotact Funct Neurosurg. 2005;83:142-7.
• Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76:1636-9.
• Ondo WG, Gollomp S, Galvez-Jimenez N. A pilot study of botulinum toxin A for headache in cervical dystonia. Headache. 2005;45:1073-7.
• Ondo WG, Lai D. Olfaction testing in patients with tremor-dominant Parkinson's disease: is this a distinct condition? Mov Disord. 2005;20:471-5.
• Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005;20:958-63.
• Ondo WG, Wang A, Thomas M, Vuong KD. Evaluating factors that can influence spirography ratings in patients with essential tremor. Parkinsonism Relat Disord. 2005;11:45-8.
• Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20:345-8.
• Ondo WG. Restless legs syndrome. Neurol Clin. 2005;23:1165-85, viii.
• Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 2005;579:6716-20.
• Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett. 2005;377:106-9.
• Ross S, Jankovic J. Palatal myoclonus: an unusual presentation. Mov Disord. 2005;20:1200-3.
• Shatunov A, Jankovic J, Elble R, Sambuughin N, Singleton A, Hallett M, Goldfarb L. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;65:1995; author reply 1995.
• Silay YS, Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005;10:365-80.
• Stojanovic R, Vasiljevic Z, Prostran M, Radovanovic M, Stefanovic B, Radovanovic N, Jankovic J, Lakicevic M, Mitrovic P, Lasica R, Nesic Z, Todorovic Z, Stojanov M. The influence of antibiotics and statins on inflammation in coronary disease. Vojnosanit Pregl. 2005;62:661-70.
• Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65:765-7.
• Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005;62:1290-5.
• Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783-91.
• Wan XH, Vuong KD, Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005;20:44-7.
• Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB, Jr., Ondo WG, Gronseth GS, Weiner WJ. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005;64:2008-20.

Collapse All | Expand All

• Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004;63:1096-8.
• Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, Lynch DR, Mathews KD, Swoboda KJ, Harris J, Soong BW, Ashizawa T, Jankovic J, Renner D, Fu YH, Ptacek LJ. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology. 2004;63:2280-7.
• Chen S, Ondo WG, Rao S, Li L, Chen Q, Wang Q. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet. 2004;74:876-85.
• de Carvalho Aguiar P, Fazzari M, Jankovic J, Ozelius LJ. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004;19:1237-8.
• Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. Jama. 2004;292:1685-6.
• Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP. Haplotype analysis at the ETM2 locus in a Singaporean sample with familial essential tremor. Clin Genet. 2004;66:353-7.
• Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-53.
• Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27:234-44.
• Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics. 2004;114:1203-5.
• Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75:951-7.
• Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004;94:275-86.
• Jankovic J. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology. 2004;63:1541-2; author reply 1541-2.
• Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19 Suppl 8:S109-15.
• Jiang C, Wan X, Jankovic J, Christian ST, Pristupa ZB, Niznik HB, Sundsmo JS, Le W. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004;27:63-73.
• Lassinger BK, Kwak C, Walford RL, Jankovic J. Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: a possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004;19:465-9.
• Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, Walter JW, Nance MA, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Small GW, Mastaglia F, Haines JL, Pericak-Vance MA, Vance JM. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62:2005-9.
• Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981-90.
• Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004;61:1393-7.
• Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37-40.
• Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27:274-7.
• Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia. 2004;24:60-5.
• Pan T, Le W, Jankovic J. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004;62:343; author reply 343-4.
• Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004;94:29-36.
• Suteerawattananon M, Morris GS, Etnyre BR, Jankovic J, Protas EJ. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004;219:63-9.
• Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004;19:692-5.
• Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004;19:36-42.
• Thomas M, Jankovic J, Suteerawattananon M, Wankadia S, Caroline KS, Vuong KD, Protas E. Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci. 2004;217:89-99.
• Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004;17:437-42.
• Thomas M, Jankovic J. Psychogenic movement disorders: diagnosis and management. CNS Drugs. 2004;18:437-52.
• Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19:1414-23.
• Wu YC, Zhao YB, Lu CZ, Qiao J, Tan YJ. Correlation between serum level of neuron-specific enolase and long-term functional outcome after acute cerebral infarction: prospective study. Hong Kong Med J. 2004;10:251-4.

Collapse All | Expand All

• Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, Earley CJ. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61:304-9.
• Handforth A, Ondo WG, Tatter S, Mathern GW, Simpson RK, Jr., Walker F, Sutton JP, Hubble JP, Jankovic J. Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial. Neurology. 2003;61:1401-5.
• He Y, Imam SZ, Dong Z, Jankovic J, Ali SF, Appel SH, Le W. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 2003;86:1338-45.
• Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, Ruszczyk MU. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003;4:185-9.
• Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003;18:1190-2.
• Hou JG, Jankovic J. Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003;206:59-64.
• Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186-8.
• Kuniyoshi SM, Jankovic J. MDMA and Parkinsonism. N Engl J Med. 2003;349:96-7.
• Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003;18:1530-3.
• Kwak C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003;60:1595-8.
• Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003;33:85-9.
• Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Mastaglia F, Middleton LT, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12:3259-67.
• Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003;10:68-79.
• Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003;26:461-81.
• Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Jr., Lozano AM, Penn RD, Simpson RK, Jr., Stacy M, Wooten GF. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60:69-73.
• Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Ondo WG, Allen FH, Jr., Scott BL, Goetz CG, Small GW, Mastaglia F, Stajich JM, Zhang F, Booze MW, Winn MP, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003;53:624-9.
• Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons KE, Pahwa R, Stern MB, Hiner BC, Jankovic J, Ondo WG, Allen FH, Jr., Scott BL, Goetz CG, Small GW, Mastaglia FL, Stajich JM, Zhang F, Booze MW, et al. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003;60:975-80.
• Ondo W. Gait and balance disorders. Med Clin North Am. 2003;87:793-801, viii.
• Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord. 2003;18:683-5.
• Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. Neurology. 2003;61:1093-7.
• Pan T, Fei J, Zhou X, Jankovic J, Le W. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003;72:1073-83.
• Pan T, Jankovic J, Le W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003;20:711-21.
• Rosa AL, Jankovic J, Ashizawa T. Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome. Arch Neurol. 2003;60:502-3.
• Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003;114:288-94.
• Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003;52:1358-70; discussion 1370-3.
• Savant CS, Singhal BS, Jankovic J, Khan M, Virani A. Substantia nigra lesions in viral encephalitis. Mov Disord. 2003;18:213-6.
• Simon DK, Friedman J, Breakefield XO, Jankovic J, Brin MF, Provias J, Bressman SB, Charness ME, Tarsy D, Johns DR, Tarnopolsky MA. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 2003;4:199-205.
• Simpkins N, Jankovic J. Neuroprotection in Parkinson disease. Arch Intern Med. 2003;163:1650-4.
• Thomas M, Le WD, Jankovic J. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003;26:18-23.
• Tintner R, Jankovic J. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003;12:1803-20.
• van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Jr., Goetz CG, Small GW, Mastaglia F, et al. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003;60:1189-91.
• van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Jr., Goetz CG, Small GW, Mastaglia F, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003;72:804-11.
• Walker RH, Jankovic J, O'Hearn E, Margolis RL. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003;18:1527-30.

Collapse All | Expand All

• Bajenaru O, Panea C, Adam O. The efficacy and limits of the treatment with botulinum toxin in focal dystonias. Therapeutics, Pharmacology and Clinical Toxicology. 2002;VI-I:89-94.
• Blakeley J, Jankovic J. Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002;89:401-20.
• Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord. 2002;17:726-34.
• Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002;31:247-62.
• Jankovic J, Demirkiran M. Classification of paroxysmal dyskinesias and ataxias. Adv Neurol. 2002;89:387-400.
• Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8:271-6.
• Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord. 2002;17:638-44.
• Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58:S19-32.
• Krauss JK, Jankovic J. Head injury and posttraumatic movement disorders. Neurosurgery. 2002;50:927-39; discussion 939-40.
• Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002;17:821-5.
• Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FA, Jr., Goetz CG, Mastaglia F, Stajich JM, Gibson RA, Middleton LT, Saunders AM, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70:985-93.
• Ondo W. Epidemiology of restless legs syndrome. Sleep Med. 2002;3 Suppl:S13-5.
• Ondo WG, Chan LL, Levy JK. Vascular parkinsonism: clinical correlates predicting motor improvement after lumbar puncture. Mov Disord. 2002;17:91-7.
• Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031-5.
• Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002;25:300-2.
• Ondo WG, Verma A. Physiological assessment of paroxysmal dystonia secondary to subacute sclerosing panencephalitis. Mov Disord. 2002;17:154-7.
• Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59:421-4.
• Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, Ozelius L. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002;17:339-45.
• Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58:341-6.
• Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002;19:245-51.
• Sabbahi M, Etnyre B, Al-Jawayed IA, Hasson S, Jankovic J. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002;19:67-72.
• Sethi KD, Jankovic J. Dystonia in spinocerebellar ataxia type 6. Mov Disord. 2002;17:150-3.
• Tintner R, Jankovic J. Treatment options for Parkinson's disease. Curr Opin Neurol. 2002;15:467-76.
• Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, Lai D, Le WD. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002;58:881-4.

Collapse All | Expand All

• Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001;56:1712-21.
• Hanna PA, Ratkos L, Ondo WG, Jankovic J. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm. 2001;108:63-70.
• Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord. 2001;16:1201-2.
• Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58:1611-5.
• Jankovic J, Lai EC, Ondo WG, Roberts-Warrior D, Olson SL, Krauss JK, Grossman RG. Effects of pallidotomy on gait and balance. Adv Neurol. 2001;87:271-81.
• Jankovic J, Nutt JG, Sudarsky L. Classification, diagnosis, and etiology of gait disorders. Adv Neurol. 2001;87:119-33.
• Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8:109-21.
• Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes!. Mov Disord. 2001;16:7-12.
• Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol. 2001;85:15-29.
• Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001;24:1568-70.
• Jankovic J. Parkinson's disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001;114:227-34.
• Jankovic J. Parkinson's disease. A half century of progress. Neurology. 2001;57:S1-3.
• Jankovic J. Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001;58:1970-2.
• Jankovic J. Tourette's syndrome. N Engl J Med. 2001;345:1184-92.
• Krauss JK, Simpson RK, Jr., Ondo WG, Pohle T, Burgunder JM, Jankovic J. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001;48:535-41; discussion 541-3.
• Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18:389-96.
• Leckman JF, Cohen DJ, Goetz CG, Jankovic J. Tourette syndrome: pieces of the puzzle. Adv Neurol. 2001;85:369-90.
• Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, DeLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, Kramer P, Brin MF, Ozelius LJ, Breakefield XO. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 2001;3:133-43.
• Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Jr., Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. Jama. 2001;286:2245-50.
• Ondo W, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001;58:218-22.
• Ondo W, Dat Vuong K, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001;16:1137-42.
• Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57:1392-6.
• Sambuughin N, Nelson TE, Jankovic J, Xin C, Meissner G, Mullakandov M, Ji J, Rosenberg H, Sivakumar K, Goldfarb LG. Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord. 2001;11:530-7.
• Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Jr., Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Slotterbeck B, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. Jama. 2001;286:2239-44.
• Shahed J, Jankovic J. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001;16:114-8.
• Swoboda KJ, Soong BW, McKenna C, Brunt ER, Litt M, Bale JF, Jr., Ashizawa T, Bennett LB, Bowcock AM, Roach ES, Gerson D, Matsuura T, Heydemann PT, Nespeca MP, Jankovic J, Leppert M, Ptacek LJ. Paroxysmal kinesigenic dyskinesia and infantile convulsions. Clinical and linkage studies. 2000. Neurology. 2001;57:S42-8.
• Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001;24:247-53.
• Tan EK, Jankovic J. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001;13:380-4.
• Tan EK, Nagamitsu S, Matsuura T, Khajavi M, Jankovic J, Ondo W, Ashizawa T. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001;305:70-2.
• Tan EK, Ondo WG. Motor restlessness. Int J Clin Pract. 2001;55:320-2.
• Tintner R, Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001;2:1985-94.
• Tintner R, Jankovic J. Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep. 2001;1:337-45.
• Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord. 2001;16:252-7.
• Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord. 2001;7:115-120.
• Xu P, Liang X, Jankovic J, Le W. Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol. 2001;58:1879-82.
• Yoshor D, Hamilton WJ, Ondo W, Jankovic J, Grossman RG. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001;48:818-24; discussion 824-6.
• Bain P, Brin M, Deuschl G, Elble R, Jankovic J, Findley L, Koller WC, Pahwa R. Criteria for the diagnosis of essential tremor. Neurology. 2000;54:S7.
• Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000;55:S15-21.
• Higgins JJ, Golbe LI, De Biase A, Jankovic J, Factor SA, Adler RL. An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. Neurology. 2000;55:1364-7.
• Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000;57:369-72.
• Jankovic J. Atypical and typical cranial dystonia following dental procedures. Mov Disord. 2000;15:366.
• Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000;55:S2-6.
• Jankovic J. Essential tremor: clinical characteristics. Neurology. 2000;54:S21-5.
• Jankovic J. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000;23:252-61.
• Kwak C, Jankovic J. Tics in Tourette syndrome and botulinum toxin. J Child Neurol. 2000;15:631-4.
• Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57:1190-3.
• Lai EC, Jankovic J, Krauss JK, Ondo WG, Grossman RG. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000;55:1218-22.
• Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm. 2000;107:1165-73.
• Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15:678-82.
• Ondo W, Tan EK, Mansoor J. Rheumatologic serologies in secondary restless legs syndrome. Mov Disord. 2000;15:321-3.
• Ondo W, Warrior D, Overby A, Calmes J, Hendersen N, Olson S, Jankovic J. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000;57:1464-9.
• Ondo WG, Ben-Aire L, Jankovic J, Lai E, Contant C, Grossman R. Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000;101:79-84.
• Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord. 2000;15:154-8.
• Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord. 2000;6:237-240.
• Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology. 2000;55:1404-6.
• Rettig GM, York MK, Lai EC, Jankovic J, Krauss JK, Grossman RG, Levin HS. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69:326-36.
• Ringman JM, Jankovic J. Occurrence of tics in Asperger's syndrome and autistic disorder. J Child Neurol. 2000;15:394-400.
• Roberts-Warrior D, Overby A, Jankovic J, Olson S, Lai EC, Krauss JK, Grossman R. Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000;123 ( Pt 10):2141-9.
• Swoboda KJ, Soong B, McKenna C, Brunt ER, Litt M, Bale JF, Jr., Ashizawa T, Bennett LB, Bowcock AM, Roach ES, Gerson D, Matsuura T, Heydemann PT, Nespeca MP, Jankovic J, Leppert M, Ptacek LJ. Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology. 2000;55:224-30.
• Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease. Mov Disord. 2000;15:171-3.
• Tan EK, Jankovic J. Hemifacial spasm and hypertension: how strong is the association? Mov Disord. 2000;15:363-5.
• Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68:186-90.
• Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000;131:211-6.
• Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000;55:533-8.
• Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000;54:1195-8.
• Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol. 2000;57:729-32.
• Tan EK, Ondo W. Restless legs syndrome: clinical features and treatment. Am J Med Sci. 2000;319:397-403.
• Uc EY, Wenger DA, Jankovic J. Niemann-Pick disease type C: two cases and an update. Mov Disord. 2000;15:1199-203.
• Vanek ZF, Jankovic J. Dystonia in corticobasal degeneration. Adv Neurol. 2000;82:61-7.
• Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000;281:167-70.
• Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431-8.
• Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity. Neurology. 1999;52:907-10.
• Hanna PA, Janjua FN, Contant CF, Jankovic J. Bilineal transmission in Tourette syndrome. Neurology. 1999;53:813-8.
• Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol. 1999;56:90-4.
• Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999;66:612-6.
• Jankovic J, Ben-Arie L, Schwartz K, Chen K, Khan M, Lai EC, Krauss JK, Grossman R. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999;14:57-62.
• Jankovic J, Lai E, Ben-Arie L, Krauss JK, Grossman R. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999;167:62-7.
• Jankovic J, Lai EC, Krauss J, Grossman R. Surgical treatment of levodopa-induced dyskinesias. Adv Neurol. 1999;80:603-9.
• Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:646-50.
• Jankovic J. New and emerging therapies for Parkinson disease. Arch Neurol. 1999;56:785-90.
• Jankovic JT, Underwood WS, Goodwin GM. Exposures from thorium contained in thoriated tungsten welding electrodes. Am Ind Hyg Assoc J. 1999;60:384-9.
• Le W, Conneely OM, He Y, Jankovic J, Appel SH. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999;73:2218-21.
• Le W, Conneely OM, Zou L, He Y, Saucedo-Cardenas O, Jankovic J, Mosier DR, Appel SH. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999;159:451-8.
• Le WD, Rowe DB, Jankovic J, Xie W, Appel SH. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999;56:194-200.
• Litvan I, Grimes DA, Lang AE, Jankovic J, McKee A, Verny M, Jellinger K, Chaudhuri KR, Pearce RK. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246 Suppl 2:II1-5.
• Mathew SJ, Yudofsky SC, McCullough LB, Teasdale TA, Jankovic J. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999;11:259-67.
• Miller CS, Gammage RB, Jankovic JT. Exacerbation of chemical sensitivity: a case study. Toxicol Ind Health. 1999;15:398-402.
• Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999;22:1-4.
• Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999;14:664-8.
• Ondo W. Ropinirole for restless legs syndrome. Mov Disord. 1999;14:138-40.
• Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279-81.
• Scott WK, Yamaoka LH, Stajich JM, Scott BL, Vance JM, Roses AD, Pericak-Vance MA, Watts RL, Nance M, Hubble J, Koller W, Stern MB, Colcher A, Allen FH, Jr., Hiner BC, Jankovic J, Ondo W, Laing NG, Mastaglia F, Goetz C, et al. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999;2:191-2.
• Stanley RK, Protas EJ, Jankovic J. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999;31:761-6.
• Tan EK, Jankovic J. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999;14:345-9.
• Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102-7.
• Watts MW, Tan EK, Jankovic J. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999;17:196-201.
• Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56:98-102.
• Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999;64:1275-85.
• Becker PM, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology. 1998;51:1221-3.
• Desaloms JM, Krauss JK, Lai EC, Jankovic J, Grossman RG. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998;89:194-9.
• Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998;50:1624-9.
• Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord. 1998;13:972-7.
• Jankovic J, Sekula S. Dermatological manifestations of Tourette syndrome and obsessive-compulsive disorder. Arch Dermatol. 1998;134:113-4.
• Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol. 1998;78:169-83.
• Jankovic J. Re-emergence of surgery for dystonia. J Neurol Neurosurg Psychiatry. 1998;65:434.
• Litvan I, Booth V, Wenning GK, Bartko JJ, Goetz CG, McKee A, Jankovic J, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm. 1998;105:217-27.
• Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969-78.
• Litvan II, Jankovic J, Goetz CG, Wenning GK, Sastry N, Jellinger K, McKee A, Lai EC, Brandel JP, Verny M, Ray-Chaudhuri K, Pearce RK, Bartko JJ, Agid Y. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. Eur J Neurol. 1998;5:451-457.
• Ondo W, Jankovic J, Schwartz K, Almaguer M, Simpson RK. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998;51:1063-9.
• Ondo WG, Desaloms JM, Jankovic J, Grossman RG. Pallidotomy for generalized dystonia. Mov Disord. 1998;13:693-8.
• Ondo WG, Harris C. Toward optimal health: the experts respond to Parkinson's disease. Interview by Jodi Godfrey Meisler. J Womens Health. 1998;7:957-62.
• Ondo WG, Jankovic J, Lai EC, Sankhla C, Khan M, Ben-Arie L, Schwartz K, Grossman RG, Krauss JK. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998;50:266-70.
• Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, Moerlein SM. Decreased [18F]spiperone binding in putamen in dystonia. Adv Neurol. 1998;78:161-8.
• Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998;13:150-4.
• Sankhla C, Lai EC, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998;65:722-8.
• Scarano VR, Jankovic J. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998;43:334-9.
• Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998;21:1740-7.
• Wang WW, Khajavi M, Patel BJ, Beach J, Jankovic J, Ashizawa T. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998;55:1521-3.
• Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, Poewe W, Jellinger K, Ray Chaudhuri K, D'Olhaberriague L, Pearce RK. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64:184-9.
• Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin North Am. 1997;20:821-38.
• Jankovic J, Beach J, Pandolfo M, Patel PI. Familial essential tremor in 4 kindreds. Prospects for genetic mapping. Arch Neurol. 1997;54:289-94.
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358-62.
• Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997;6:S129-45.
• Jankovic J, Hamilton WJ, Grossman RG. Thalamic surgery for movement disorders. Adv Neurol. 1997;74:221-33.
• Jankovic J, Ruzicka E. [Tics and Tourette's syndrome]. Cas Lek Cesk. 1997;136:399-404.
• Jankovic J, Scott BL, Evans RW. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1997;12:818.
• Jankovic J. Tourette syndrome. Phenomenology and classification of tics. Neurol Clin. 1997;15:267-75.
• Krauss JK, Desaloms JM, Lai EC, King DE, Jankovic J, Grossman RG. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997;87:358-67.
• Krauss JK, Grossman RG, Jankovic J. Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov Disord. 1997;12:124-6.
• Krauss JK, Grossman RG, Lai EC, Schwartz K, Jankovic J. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997;58:153-62.
• Krauss JK, Jankovic J, Lai EC, Rettig GM, Grossman RG. Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. Arch Neurol. 1997;54:1026-9.
• Krauss JK, Jankovic J. Hemidystonia secondary to carotid artery gunshot injury. Childs Nerv Syst. 1997;13:285-8.
• Krauss JK, Jankovic J. Tics secondary to craniocerebral trauma. Mov Disord. 1997;12:776-82.
• Krauss JK, Seeger W, Jankovic J. Cervical dystonia associated with tumors of the posterior fossa. Mov Disord. 1997;12:443-7.
• Krauss JK, Toups EG, Jankovic J, Grossman RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997;63:642-8.
• Le W, Jankovic J, Xie W, Kong R, Appel SH. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett. 1997;224:197-200.
• Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701-7.
• Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, Lai EC, Verny M, Ray-Chaudhuri K, McKee A, Jellinger K, Pearce RK, Bartko JJ. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48:119-25.
• Litvan I, Agid Y, Sastry N, Jankovic J, Wenning GK, Goetz CG, Verny M, Brandel JP, Jellinger K, Chaudhuri KR, McKee A, Lai EC, Pearce RK, Bartko JJ. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology. 1997;49:62-9.
• Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, McKee A, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997;54:937-44.
• Ondo W. Lingual dystonia following electrical injury. Mov Disord. 1997;12:253.
• Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, Moerlein SM. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997;17:843-50.
• Alford RL, Ashizawa T, Jankovic J, Caskey CT, Richards CS. Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am J Med Genet. 1996;66:281-6.
• Ashizawa T, Jankovic J. Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord. 1996;11:457-9.
• Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157-64.
• Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology. 1996;46:1040-3.
• Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsopulos T, Brower CA, Chapieski L, Trinidad K, Como P, Jankovic J. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology. 1996;46:965-8.
• Jankovic J, Drake F. A screening method for occupational reproductive health risk. Am Ind Hyg Assoc J. 1996;57:641-9.
• Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250-6.
• Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry. 1996;60:704.
• Jankovic JT, Ihle R, Vick DO. Occupant generated carbon dioxide as a measure of dilution ventilation efficiency. Am Ind Hyg Assoc J. 1996;57:756-9.
• Krauss JK, Akeyson EW, Giam P, Jankovic J. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996;83:420-22.
• Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996;11:563-6.
• Krauss JK, Jankovic J. Surgical treatment of Parkinson's disease. Am Fam Physician. 1996;54:1621-9.
• Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1-9.
• Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, Wenning G, D'Olhaberriague L, Verny M, Chaudhuri KR, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RK. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46:922-30.
• Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996;46:720-6.
• Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47:1435-41.
• Ondo WG, Delong GR. Dandy-Walker syndrome presenting as opisthotonus: proposed pathophysiology. Pediatr Neurol. 1996;14:165-8.
• Protas EJ, Stanley RK, Jankovic J, MacNeill B. Cardiovascular and metabolic responses to upper- and lower-extremity exercise in men with idiopathic Parkinson's disease. Phys Ther. 1996;76:34-40.
• Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1996;11:748-51.
• Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996;11:431-3.
• Scott BL, Jankovic J. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996;46:68-74.
• Cardoso F, Jankovic J, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995;36:501-7; discussion 507-8.
• Cardoso F, Jankovic J. Clinical use of botulinum neurotoxins. Curr Top Microbiol Immunol. 1995;195:123-41.
• Cardoso F, Jankovic J. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995;52:263-70.
• Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardoso F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995;7:471-5.
• Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995;38:571-9.
• Jankovic J, Ashizawa T. Tourettism associated with Huntington's disease. Mov Disord. 1995;10:103-5.
• Jankovic J, Beach J, Ashizawa T. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995;32:516-8.
• Jankovic J, Beach J, Schwartz K, Contant C. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995;45:645-8.
• Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995;37:680-6; discussion 686-7.
• Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743-6.
• Jankovic J. Apraxia of lid opening. Mov Disord. 1995;10:686-7.
• Jankovic J. International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. Mov Disord. 1995;10:533-40.
• Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18:197-214.
• McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W, Lang AE, Olanow CW, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995;52:565-70.
• Perkins AT, Ondo W. When to worry about headache. Head pain as a clue to intracranial disease. Postgrad Med. 1995;98:197-201, 204-8.
• Shulman LM, Lang AE, Jankovic J, David NJ, Weiner WJ. Case 1, 1995: psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. Mov Disord. 1995;10:257-62.
• Ashizawa T, Wong LJ, Richards CS, Caskey CT, Jankovic J. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994;44:1137-43.
• Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem. 1994;62:1631-4.
• Jankovic J, Shoulson I, Weiner WJ. Early-stage Parkinson's disease: to treat or not to treat. Neurology. 1994;44:S4-7.
• Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol. 1994;7:358-66.
• Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994;9:347-9.
• Jankovic J. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994;44:2006-14.
• Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9:40-7.
• Percy AK, Glaze DG, Schultz RJ, Zoghbi HY, Williamson D, Frost JD, Jr., Jankovic JJ, del Junco D, Skender M, Waring S, et al. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35:464-70.
• Piwinski SE, Jankovic J, McElligott MA. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994;34:466-71.
• Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:189-201.
• Wojcieszek J, Lang AE, Jankovic J, Greene P, Deck J. What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. Mov Disord. 1994;9:358-66.
• Cardoso F, Jankovic J. Movement disorders. Neurol Clin. 1993;11:625-38.
• Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord. 1993;8:175-8.
• Cardoso FE, Jankovic J. Hereditary motor-sensory neuropathy and movement disorders. Muscle Nerve. 1993;16:904-10.
• Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci. 1993;5:206-8.
• Jankovic J, Contant C, Perlmutter J. Essential tremor and PD. Neurology. 1993;43:1447-9.
• Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95:38-48.
• Jankovic J, Rajput AH, Golbe LI, Goodman JC. What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993;8:525-32.
• Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993;43:834-6.
• Jankovic J, Schwartz KS. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg [Am]. 1993;18:883-7.
• Jankovic J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol. 1993;50:286-8.
• Monday K, Jankovic J. Psychogenic myoclonus. Neurology. 1993;43:349-52.
• Ondo WG, Hurwitz BJ. Tardive dyskinesia and pseudo-parkinsonism. In a nursing home patient who itched. N C Med J. 1993;54:605-7.
• Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993;43:937-41.
• Stacy M, Jankovic J. Childhood dystonia. Pediatr Ann. 1993;22:53-8.
• Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Annu Rev Med. 1993;44:431-40.
• Burnett L, Jankovic J. Chorea and ballism. Curr Opin Neurol Neurosurg. 1992;5:308-13.
• Doody RS, Jankovic J. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992;55:806-10.
• Friedman DI, Jankovic J, McCrary JA, 3rd. Neuro-ophthalmic findings in progressive supranuclear palsy. J Clin Neuroophthalmol. 1992;12:104-9.
• Jankovic J, Wooten M, Van der Linden C, Jansson B. Low body weight in Parkinson's disease. South Med J. 1992;85:351-4.
• Jankovic J. Diagnosis and classification of tics and Tourette syndrome. Adv Neurol. 1992;58:7-14.
• Lew H, Jordan C, Jerger J, Jankovic J. Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992;42:594-7.
• Miller LG, Jankovic J. Persistent dystonia possibly induced by flecainide. Mov Disord. 1992;7:62-3.
• Stacy M, Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. Neurol Clin. 1992;10:341-59.
• Stacy M, Jankovic J. Tardive tremor. Mov Disord. 1992;7:53-7.
• Blum P, Jankovic J. Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991;6:12-20.
• FitzGerald PM, Jankovic J. Orthostatic tremor: an association with essential tremor. Mov Disord. 1991;6:60-4.
• Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186-94.
• Jankovic J, Jones W, Burkhart J, Noonan G. Environmental study of firefighters. Ann Occup Hyg. 1991;35:581-602.
• Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41:1088-91.
• Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology. 1991;41:1185-8.
• Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991;48:1253-6.
• Jankovic J, Stone L. Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991;6:248-52.
• Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology. 1991;41:234-8.
• Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal baclofen for intractable axial dystonia. Neurology. 1991;41:1141-2.
• Narayana PA, Slopis JM, Jackson EF, Jankovic J, Butler IJ. Proton magnetic resonance spectroscopic studies of hypertrophied muscle. Effect of botulinum toxin treatment. Invest Radiol. 1991;26:58-64.
• Stone LA, Jankovic J. The coexistence of tics and dystonia. Arch Neurol. 1991;48:862-5.
• Taylor LD, Krizman DB, Jankovic J, Hayani A, Steuber PC, Greenberg F, Fenwick RG, Caskey CT. 9p monosomy in a patient with Gilles de la Tourette's syndrome. Neurology. 1991;41:1513-5.
• Carter JB, Patrinely JR, Jankovic J, McCrary JA, 3rd, Boniuk M. Familial hemifacial spasm. Arch Ophthalmol. 1990;108:249-50.
• FitzGerald PM, Jankovic J, Glaze DG, Schultz R, Percy AK. Extrapyramidal involvement in Rett's syndrome. Neurology. 1990;40:293-5.
• FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord. 1990;5:195-202.
• Jankovic J, Friedman DI, Pirozzolo FJ, McCrary JA. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990;53:293-304.
• Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40:1529-34.
• Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53:633-9.
• Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40:277-80.
• Jankovic J. Lower body (vascular) parkinsonism. Arch Neurol. 1990;47:728.
• Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83:525-32.
• Miller LG, Jankovic J. Sulpiride-induced tardive dystonia. Mov Disord. 1990;5:83-4.
• Persing JA, Muir A, Becker DG, Jankovic JJ, Anderson RL, Edlich RF. Blepharospasm-oromandibular dystonia associated with a left cerebellopontine angle meningioma. J Emerg Med. 1990;8:571-4.
• Beall SS, Patten BM, Mallette L, Jankovic J. Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr's syndrome. Ann Neurol. 1989;26:569-75.
• Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4:157-75.
• Dewey RB, Jr., Jankovic J. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989;46:862-7.
• FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4:249-60.
• FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology. 1989;39:1434-7.
• Jankovic J, Grossman R, Goodman C, Pirozzolo F, Schneider L, Zhu Z, Scardino P, Garber AJ, Jhingran SG, Martin S. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 1989;39:1227-34.
• Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989;4:303-9.
• Jankovic J, Shale H. Dystonia in musicians. Semin Neurol. 1989;9:131-5.
• Jankovic J. Essential tremor and Parkinson's disease. Ann Neurol. 1989;25:211-2.
• Jankovic J. Parkinsonism-plus syndromes. Mov Disord. 1989;4 Suppl 1:S95-119.
• Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989;149:2486-92.
• Nath A, Jankovic J. Motor disorders in patients with human immunodeficiency virus infection. Prog AIDS Pathol. 1989;1:159-66.
• Jankovic J, Armstrong D, Low NL, Goetz CG. Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. Mov Disord. 1988;3:352-61.
• Jankovic J, Armstrong D, Low NL, Rapin I. Case 3, 1988. Progressive myoclonic epilepsy, dementia, and blindness in a young girl. Mov Disord. 1988;3:362-9.
• Jankovic J, Caskey TC, Stout JT, Butler IJ. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988;23:466-9.
• Jankovic J, Nutt JG. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988;49:117-23.
• Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38:391-4.
• Jankovic J, Van der Linden C. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988;51:1512-9.
• Jankovic J. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988;50:583-91.
• Jankovic J. Botulinum A toxin in the treatment of blepharospasm. Adv Neurol. 1988;49:467-72.
• Jankovic J. Cranial-cervical dyskinesias: an overview. Adv Neurol. 1988;49:1-13.
• Jankovic J. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988;49:103-16.
• Jankovic J. Hemiparkinsonism and hemiatrophy. Neurology. 1988;38:1815-6.
• Jankovic J. Orofacial and other self-mutilations. Adv Neurol. 1988;49:365-81.
• Jankovic J. Parkinson's disease: recent advances in therapy. South Med J. 1988;81:1021-7.
• Percy AK, Zoghbi HY, Lewis KR, Jankovic J. Rett syndrome: qualitative and quantitative differentiation from autism. J Child Neurol. 1988;3 Suppl:S65-7.
• Rosenbaum F, Jankovic J. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988;38:522-7.
• Singh SK, Jankovic J. Tardive dystonia in patients with Tourette's syndrome. Mov Disord. 1988;3:274-80.
• Amandus HE, Wheeler R, Jankovic J, Tucker J. The morbidity and mortality of vermiculite miners and millers exposed to tremolite-actinolite: Part I. Exposure estimates. Am J Ind Med. 1987;11:1-14.
• Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology. 1987;37:570-6.
• Jankovic J, Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987;10:511-21.
• Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616-23.
• Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol. 1987;45:551-4.
• Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord. 1987;2:159-63.
• Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987;14:541-6.
• Koller W, O'Hara R, Weiner W, Lang A, Nutt J, Agid Y, Bonnet AM, Jankovic J. Relationship of aging to Parkinson's disease. Adv Neurol. 1987;45:317-21.
• Kurlan R, Jankovic J, Rubin A, Patten B, Griggs R, Shoulson I. Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? Arch Neurol. 1987;44:1057-60.
• Little JT, Jankovic J. Tardive myoclonus. Mov Disord. 1987;2:307-11.
• Miller RH, Woodson GE, Jankovic J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg. 1987;113:603-5.
• Nath A, Jankovic J, Pettigrew LC. Movement disorders and AIDS. Neurology. 1987;37:37-41.
• Friedman DI, Jankovic J, Rolak LA. Arteriovenous malformation presenting as hemidystonia. Neurology. 1986;36:1590-3.
• Gospe SM, Jr., Jankovic J. Drug-induced dystonia in neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1986;2:236-7.
• Inbody S, Jankovic J. Hyperkinetic mutism: bilateral ballism and basal ganglia calcification. Neurology. 1986;36:825-7.
• Jankovic J, Fahn S. The phenomenology of tics. Mov Disord. 1986;1:17-26.
• Jankovic J, Newmark M, Peter P. Parkinsonism and acquired hydrocephalus. Mov Disord. 1986;1:59-64.
• Jankovic J, Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology. 1986;36:303-4.
• Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol. 1986;43:1025-31.
• Jankovic J, Reches A. Parkinson's disease in monozygotic twins. Ann Neurol. 1986;19:405-8.
• Jankovic J. Blepharospasm with basal ganglia lesions. Arch Neurol. 1986;43:866-8.
• Jankovic J. Myoglobinuric renal failure in Huntington's chorea. Neurology. 1986;36:138-9.
• Jankovic J. Recent advances in the management of tics. Clin Neuropharmacol. 1986;9 Suppl 2:S100-10.
• Jankovic J. Whipple's disease of the central nervous system in AIDS. N Engl J Med. 1986;315:1029-30.
• Wells CR, Jankovic J. Familial spastic paraparesis and deafness. A new x-linked neurodegenerative disorder. Arch Neurol. 1986;43:943-6.
• Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson's disease. Ann Neurol. 1985;17:329-33.
• Jankovic J, Glass JP. Metoclopramide-induced phantom dyskinesia. Neurology. 1985;35:432-5.
• Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology. 1985;35:227-34.
• Jankovic J, Orman J, Jansson B. Placebo-controlled study of mesulergine in Parkinson's disease. Neurology. 1985;35:161-5.
• Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology. 1985;35:296-9.
• Jankovic J. Long-term use of dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 1985;8:131-40.
• Jankovic J. Progressive supranuclear palsy: paraneoplastic effect of bronchial carcinoma. Neurology. 1985;35:446-7.
• Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol. 1985;17:505-9.
• Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry. 1985;48:650-7.
• Reshef E, Greenberg SB, Jankovic J. Herpes zoster ophthalmicus followed by contralateral hemiparesis: report of two cases and review of literature. J Neurol Neurosurg Psychiatry. 1985;48:122-7.
• Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985;35:366-70.
• Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology. 1985;35:522-6.
• Zetusky WJ, Jankovic J. Laterality and symptom association in Parkinson's disease. Arch Neurol. 1985;42:1132-3.
• Fahn S, Jankovic J. Practical management of dystonia. Neurol Clin. 1984;2:555-69.
• Glass JP, Jankovic J, Borit A. Hemiballism and metastatic brain tumor. Neurology. 1984;34:204-7.
• Hanke W, Sepulveda MJ, Watson A, Jankovic J. Respiratory morbidity in wollastonite workers. Br J Ind Med. 1984;41:474-9.
• Jankovic J, Glaze DG, Frost JD, Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology. 1984;34:688-92.
• Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol. 1984;16:371-6.
• Jankovic J. Progressive supranuclear palsy. Clinical and pharmacologic update. Neurol Clin. 1984;2:473-86.
• Evans BK, Jankovic J. Tuberous sclerosis and chorea. Ann Neurol. 1983;13:106-7.
• Glaze DG, Frost JD, Jr., Jankovic J. Sleep in Gilles de la Tourette's syndrome: disorder of arousal. Neurology. 1983;33:586-92.
• Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol. 1983;13:273-8.
• Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol. 1983;13:402-11.
• Jankovic J, Patel SC. Blepharospasm associated with brainstem lesions. Neurology. 1983;33:1237-40.
• Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology. 1983;33:505-7.
• Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol. 1983;37:277-89.
• Levy RS, Jankovic J. Placebo-induced conversion reaction: a neurobehavioral and EEG study of hysterical aphasia, seizure, and coma. J Abnorm Psychol. 1983;92:243-9.
• Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia and inappropriate use of neuroleptic drugs. Lancet. 1982;1:1299.
• Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32:1335-46.
• Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. Jama. 1982;248:3160-4.
• Jankovic J, Penn AS. Severe dystonia and myoglobinuria. Neurology. 1982;32:1195-7.
• Jankovic J. Management of motor side effects of chronic levodopa therapy. Clin Neuropharmacol. 1982;5 Suppl 1:S19-28.
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11:41-7.
• Jankovic J, Frost JD, Jr. Quantitative assessment of parkinsonian and essential tremor: clinical application of triaxial accelerometry. Neurology. 1981;31:1235-40.
• Jankovic J. Drug-induced and other orofacial-cervical dyskinesias. Ann Intern Med. 1981;94:788-93.
• Jankovic J. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency? Ann Neurol. 1981;10:64-5.
• Porter M, Jankovic J. Benign coital cephalalgia. Differential diagnosis and treatment. Arch Neurol. 1981;38:710-2.
• Ashizawa T, Patten BM, Jankovic J. Meige's syndrome. South Med J. 1980;73:863-6.
• Jankovic J, Derman H, Armstrong D. Haemorrhagic complications of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1980;43:76-81.
• Jankovic J, Fahn S. Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med. 1980;93:460-5.
• Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979;6:227-31.
• Jankovic J, Rivera V. Hereditary myoclonus and progressive muscular atrophy: a new syndrome. Trans Am Neurol Assoc. 1978;103:116-8.